Watch ABUS. Know when insiders buy.
One email the day a filing lands. Free.
ABUS
Arbutus Biopharma Corp
4.18
−0.15 −3.46%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · shorts 44
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $827MP/E 5.3DIV YIELD —FCF YIELD —REV TTM $181.7M +1078.8%NET INCOME $153.1MNET CASH $19.2M52W 3.67 – 5.22SEC XBRL · TTM TO Invalid Date
Who holds it
None of the 15 tracked funds disclose ABUS in their latest 13F. The funds we follow.
13F filings cover US-listed holdings and arrive up to 45 days after quarter end, so positions may have changed since.
Stakes of 5% or more
Morgan Stanley and 1 related12.2%
Roivant Sciences Ltd.19.5%
“Item 4 is hereby amended by adding the following to the end thereof: On August 24, 2026, the Issuer commenced a modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its Common Shares at prices between US$5.00 and US$5.75 per Common Share (the "Offer"), wh…”
Whitefort Capital Master Fund, LP and 5 related8.0%
A 13D means the holder crossed 5% with intent beyond passive ownership and had to state a purpose; a 13G is the passive version. Every new 13D on tracked companies.